2024 MGFA SCIENTIFIC SESSION POSTER LIST AND NUMBERS

Scroll down to view all MGFA poster titles and onsite numbers that were submitted and accepted. MG numbers represent actual poster locations at the AANEM conference and Muscle & Nerve numbers are specifically listed in the AANEM published supplement.

 

MGFA Scientific Session Poster Titles and location numbers

MG Poster Location NumberMuscle&Nerve#First NameLast NameSuffixPoster Title
MG 1106Samreen AhmedMBBSA Text Messaging-Based Patient Education Program Aimed At Improving Outcomes In Myasthenia Gravis.
MG 240MariaAit-TihyatyPhDDisease Burden In Patients With Generalized Myasthenia Gravis
MG 378MariaAit-TihyatyPhDPartnering With Patients And Caregivers To Guide The Development Of Impactful Study Engagement Tools In A Generalized Myasthenia Gravis Real World Study
MG 497MariaAit-TihyatyPh.DNipocalimab, A New Neonatal Fragment Crystallizable Blocker, Leads To Rapid, Substantial And Sustained Generalized Myasthenia Gravis Disease Control
MG 513MayraAldecoaFellowshipTranscriptome-Wide And Stratified Genomic Structural Equation Modeling Identify Neurobiological Pathways Shared Across Myasthenia Gravis And Neuropsychiatric Disorders
MG 6105PriyanshuBansalMDReview Of Efficacy Of New Complement Inhibiting Monoclonal Antibodies In Myasthenia Gravis: A Real World Experience From A Tertiary Neurology Center.
MG 754TaylorBaumanBSIs Residual Serum Fibrinogen A Biomarker For Myasthenia Gravis? 
MG 865Sara BenitezMDTreatment Related Infection In Myasthenia Gravis
MG 956RatnaBhavaraju-SankaMDPatterns Of Efgartigimod Dosing In Clinical Practice In The United States
MG 1083AlexandraBonnerMDDetermination Of The Optimal Compound Muscle Action Potential Amplitude Decrement Cutoff Values In The Diagnosis Of Myasthenia Gravis Using Repetitive Nerve Stimulation Studies  
MG 1160MartinBrandhoj SkovPh.D.Unmet Needs In Myasthenia Gravis: Patient And Physician Perspectives
MG 124JiaxinChenMD, PhDTherapeutic Plasma Exchange In Achr-Ab Positive Generalized Myasthenia Gravis: A Real World Study About Its Early Response
MG 1321JiaxinChenMD, PhDCan Non-Thymomatous Late-Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review And Meta-Analysis
MG 1431PeiChenMD, PhDExtraocular Muscle Volume On Time-Of-Flight Magnetic Resonance Angiography In Patients With Myasthenia Gravis
MG 1532PeiChenMD, PhDConventional Dendritic Cells Are More Activated In The Hyperplastic Thymus Of Myasthenia Gravis Patients
MG 1667ZiaChoudhryMD, PhD, MBALeveraging Ai To Characterize Mental Health Experiences Throughout The Myasthenia Gravis Diagnosis Journey
MG 1768ZiaChoudhryMD, PhD, MBAUncontrolled Myasthenia Gravis Can Contribute To Additional Stress Burden And Adverse Mental Health Experiences
MG 1869ZiaChoudhryMD, PhD, MBASentiment Analysis Of Digital Conversations Related To Myasthenia Gravis By Race/Ethnicity
MG 1933MartaCossuMD, PhDA Randomized, Open-Label Study On The Effect Of Nipocalimab On Vaccine Responses In Healthy Participants
MG 2092DubravkaDodigMD, BSc, FRCPCDismantling Of Neuromuscular Junction In Myasthenia Gravis – A Point Of No Return
MG 21110EleniDrakouMDIdentifying Healthcare Disparities In Myasthenia Gravis: A Post-Covid-19 Pandemic Bronx Tale
MG 2236RebeccaDuttaMDRecessive Syt2-Congenital Myasthenic Syndrome Caused By A Maternal Uniparental Disomy Of Chromosome 1 
MG 2311ChristopherEvansMD (Candidate)A Study Of The Common Factors That Influence Fatigue In Myasthenia Gravis
MG 2464ConstantineFarmakidisMDLong-Term Safety And Efficacy Of Nipocalimab In Generalized Myasthenia Gravis: Vivacity-Mg3 Open-Label Interim Analysis 
MG 25103ConstantineFarmakidisMDSymptom Severity Assessment Using Mg-Adl Items And Domains In A 24-Week, Phase 3 Study (Vivacity) Of Nipocalimab In Generalized Myasthenia Gravis.
MG 2624AlexanderFayMD, PhDSeronegative Myasthenia Gravis In Children With Autoinflammatory Syndromes
MG 2752MiriamFreimerMDSwitching To Subcutaneous Zilucoplan From Iv Complement Component 5 Inhibitors In Myasthenia Gravis: A Phase 3B Study
MG 2861MiriamFreimerMDCorticosteroid Dose Tapering During Treatment With Zilucoplan In Patients With Generalized Myasthenia Gravis: 120-Week Follow-Up Of Raise-Xt
MG 2957Rachana K.Gandhi MehtaMDSelf-Administration Of Subcutaneous Rozanolixizumab In Patients With Generalized Myasthenia Gravis: Clinical Study Design
MG 301MariamGigilashviliM.D.Unique Case Of Post-Covid19 Myasthenia Gravis With Spontaneous Resolution
MG 3163CynthiaQiDirReal-World Reduction In Oral Corticosteroid Utilization At 1-Year Following Efgartigimod Initiation 
MG 3295JeffreyGuptillMDDose Selection And Clinical Development Of Efgartigimod Ph20 Subcutaneous In Patients With Generalized Myasthenia Gravis
MG 3322KellyGwathmeyMDCyclic And Every-Other-Week Dosing Of Intravenous Efgartigimod For Generalized Myasthenia Gravis: Part A Of Adapt Nxt
MG 3498Kelly G.GwathmeyMDEvaluation Of The Indirect And Nonmedical Impacts Of Generalized Myasthenia Gravis On Patients And Caregivers
MG 3581Ali A.HabibMDRozanolixizumab Treatment Patterns In Patients With Generalized Myasthenia Gravis: Post Hoc Analysis
MG 3648AidenHaghikiaMDDesign Of Kysa-6, A Phase 2, Open-Label, Multicenter Study Of Kyv-101, A Novel Fully Human Anti-Cd19 Chimeric Antigen Receptor T-Cell Therapy In Refractory Generalized Myasthenia Gravis
MG 379LaurenHerreraMDMismatch Between Neuromuscular Specialists And Myasthenia Gravis Patients In The Us Medicare Population
MG 38102JamesHowardMDDesign Of A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Subcutaneous Efgartigimod Ph20 Administered By Prefilled Syringe In Adults With Ocular Mg
MG 3937James F.Howard JrMDPhase 3 Trial Investigating Impact Of Intravenous Efgartigimod In Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
MG 4074James F.Howard Jr.MDLong-Term Safety And Efficacy Of Zilucoplan In Generalized Myasthenia Gravis: 120-Week Interim Analysis Of Raise-Xt
MG 4175James F.Howard Jr.MDDeveloping Needs-Driven Medical Education For Healthcare Professionals In Myasthenia Gravis
MG 4299James F.Howard Jr.MD, FAANThe Phase 3 Prevail Study Assessing The Efficacy And Safety Of Subcutaneous Gefurulimab In Adults With Generalized Myasthenia Gravis: Trial In Progress
MG 4314James F.Howard, Jr.MDDevelopment Of A Myasthenia Gravis Patient Journey Map As A Tool To Identify Challenges And Unmet Needs In The Patient Community 
MG 44107SazanIsmaelPhDDeveloping Musk L-Cba To Detect Anti-Musk Antibody
MG 4570LouisJacksonPharmDFactors Influencing Exacerbations And Crises In Generalized Myasthenia Gravis: Findings From A Claims Database Study
MG 4671LouisJacksonPharmDImpact Of Race And Social Determinants Of Health On Exacerbations In Generalized Myasthenia Gravis
MG 4720HenryKaminskiMDQuantitating Factors Influencing The Myasthenia Gravis Telehealth Examination
MG 4887HenryKaminskiMDOral Cladribine Capsules For Generalized Myasthenia Gravis: Design Of An Actively-Recruiting Phase 3 Clinical Study – The Myclad Study 
MG 4973HansKatzbergMDSafety And Efficacy Of Subcutaneous Immunoglobulin In Patients With Generalized Myasthenia Gravis
MG 5034AnoshaKhanN/ATowards A Genome-Wide Association For Musk Myasthenia Gravis
MG 5189FatemehKhani-HabibabadiPhDDistribution And Temporal Changes Of Autoantibody-Mediated Pathogenic Mechanisms Among Achr-Positive Mg Patients
MG 5239VeraKiyasovaMD, PhDNmd670, A First-In-Class Skeletal Muscle Clc-1 Inhibitor In Myasthenia Gravis: The Synapse-Mg Dose-Finding Study 
MG 5384VeraKiyasovaMD, PhDClc-1 Inhibition Improves Qmg Score And Skeletal Muscle Function In Patients With Myasthenia Gravis
MG 54108TylerKrallBSClinical Outcomes Of Adult Myasthenia Gravis Patients On Efgartigimod: A Retrospective Chart Review
MG 5523YuebingLiMD, PhDEpidemiological Study Of Myasthenia Gravis In Elderly Us Population: A Longitudinal Analysis Of The Medicare Claims Database From 2006-2019
MG 5649HuiningLiDoctorateTreatment Strategy Towards Myasthenia Gravis With Gad65-Igg Associated Neurological Disorders
MG 5788Yingkai (Kevin)LiMDImbalanced Pro-Inflammatory Immune Responses In Seropositive And Seronegative Mg  
MG 58100Cathy Meng FeiLiMDMediastinal Radiotherapy For Non-Operable Thymoma With Myasthenia Gravis 
MG 5994AlexisLizarragaMDComorbidities In Seropositive And Seronegative Myasthenia Gravis: A Single Center Experience
MG 6015ChingLumPharmDPozelimab And Cemdisiran Combination Therapy In Patients With Myasthenia Gravis: Phase 3 Nimble Trial Design
MG 617SushanLuoMD,PhDClinical Outcome In Impending Myasthenic Crisis: A Prospective Cohort Study
MG 62112LindsayMalatestaMDAlternative Dosing Of Efgartigimod In Myasthenia Gravis
MG 638JuliaManassonMDPreclinical Pharmacology Of S-1117, A Novel Engineered Fc-Fused Igg Cleaving Enzyme, For Chronic Treatment Of Autoantibody-Mediated Diseases Including Myasthenia Gravis 
MG 6458AlexandraMcMillanBS, MS, MDSimultaneous Myasthenia Gravis-Polymyositis Overlap Syndrome, A Case Report
MG 6518Lesley-AnnMiller-WilsonPhD, MS, MBACharacteristics And Treatment Patterns Of A United States Generalized Myasthenia Gravis Population: Interim Analysis Of Real-World Data 
MG 6628Lesley-AnnMiller-WilsonPhD, MS, MBAEvidence Gap Analysis Of The Burden Of Disease And Treatment Of Myasthenia Gravis
MG 6746AliMousaviMDEnhanced Laboratory Detection Of Anti-Acetylcholine Receptor Antibody Contributes To Rising Incidence Myasthenia Gravis 
MG 6893SrikanthMuppidiMDObserved Efficacy Of Efgartigimod In Generalized Myasthenia Gravis Across Patient Subgroups In The Adapt-Sc+ Study 
MG 695LaurenNguyenM.Sc.One Patient With Three Antibody- Confirmed Neurological Autoimmune Syndromes: A Case Report
MG 7041RichardNowakMD, MSRandomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study Of Inebilizumab In Patients With Generalized Myasthenia Gravis (Mint): Topline Efficacy And Safety Findings
MG 7144RichardNowakMD, MSThe Myasthenia Gravis Patient Registry: Characteristics, Insights, And Learnings After A Decade (2013-23)
MG 7286Richard J.NowakMD, MSChange In Concomitant Immunosuppressive Therapies For Generalized Myasthenia Gravis In Patients Receiving Complement C5 Inhibitor Therapies: A Retrospective Analysis Of Registry Data
MG 73109RichardNowakMD, MSExploring Outcomes And Characteristics Of Myasthenia Gravis 2 (Explore-Mg2): Design, Rationale, And Baseline Results
MG 74111Ananda PandurangaduMDExpediting Myasthenia Gravis Diagnostic Evaluation: A Novel, Proof-Of-Concept Tool For Undiagnosed, Symptomatic Patients That Uses Social Media Targeting And Self-Assessment 
MG 7555ShiraliPandyaMPH, PhDIncidence And Outcome Of Meningococcal Infection With Eculizumab Or Ravulizumab In Patients With Gmg Or Nmosd: An Analysis Of Us Clinical Practice
MG 7651Robert M.PascuzziMDEffect Of Rozanolixizumab On Myasthenia Gravis–Specific Outcome Subdomain Scores: Post Hoc Analyses From The Phase 3 Mycaring Study
MG 77114MamathaPasnoorMDSafety And Tolerability Of Whole-Body Electrical Muscle Stimulation Exercise In Adults With Myasthenia Gravis: A Preliminary Analysis
MG 783SherylPeaseMBAAssessing The Suitability Of The Neuro-Qol Fatigue To Evaluate Fatigue In Patients Living With Myasthenia Gravis
MG 79104TefaniPereraMDFeasibility Of 12 Weeks Of Remote Monitoring In Generalized Myasthenia Gravis
MG 8012Prashanth PouloseDM NeurologyImaging Patterns In Congenital Myasthenic Syndrome (Cms) – Insights From Mri
MG 8126AnnaPungaMD, PhDVisualization And Characterization Of Complement Activation In Acetylcholine Receptor Antibody Seropositive Myasthenia Gravis
MG 8229AnnaPungaMD, PhDShort-Term Changes In Serum Mirna Levels And Patient-Reported Outcomes In Myasthenia Gravis 
MG 8345AnnaPungaMD, PhDElevated C1S/C1-Inh In Serum And Plasma Of Myasthenia Gravis Patients 
MG 8447AnnaPungaMD, PhDA Serum Inflammatory Protein Biomarker Profile Defines Acetylcholine Receptor Antibody Seropositive Myasthenia Gravis 
MG 8517ManviPunukolluBSComparative Efficacy Of Treatment Modalities In Myasthenia Gravis
MG 8659CynthiaQiN/AExploring The Impact Of Nonsteroidal Immunosuppressive Drugs And Steroids On The Development Of Comorbidities In Patients With Myasthenia Gravis In The National Veterans Affairs Health Network
MG 8780CynthiaQiMBAQuality Of Life Of Ocular Mg Patients With Persistent Symptoms: Comparison With The General Population
MG 8825ChuanQinMD, PhDAnti-Bcma Car T-Cell Therapy In Patients With Refractory Myasthenia Gravis
MG 8935VijayaraghavaRaoPhDSteroid Use, Toxicity, And Monitoring In Patients With Generalized Myasthenia Gravis: A Survey Of Neurologists In The United States
MG 9090BhaskarRoyMBBSProteomic Analysis Reveals A Distinct Immunological Signature For Late-Onset Myasthenia Gravis
MG 91101ChloeSaderPharmDSafety Outcomes In Pregnant Patients Treated With The Complement 5 Inhibitor Therapy (C5It) Eculizumab
MG 9285Christopher A.ScheinerMD, PhDOutcomes For Patients With Generalized Myasthenia Gravis Prescribed Ravulizumab, Eculizumab, Or Efgartigimod Treatment: Interim Analysis Of A Retrospective Medical Record Analysis (Elevate) 
MG 9376JohnSheehanPhDPerinatal Treatment Patterns In Myasthenia Gravis
MG 9477JohnSheehanPhDAdverse Pregnancy Outcomes In  Myasthenia Gravis: A Retrospective Cohort Study In A Us Health Insurance Claims Database 
MG 9596PatriciaSikorsiPhDAlterations In Peripheral B And T Cell Subsets In Musk-Mg Subjects After Rituximab Treatment 
MG 9619NicholasSilvestriMDReal-World Experience With Individualized Dosing Of Efgartigimod In Patients With Generalized Myasthenia Gravis
MG 9782MartinSkovPhDClc-1 Inhibition Improves Skeletal Muscle Function In Rat Models And Patients With Myasthenia Gravis.
MG 9872A. GordonSmithMDComparative Risk-Benefit Profiles Of Immunomodulatory Therapies For Patients With Generalized Myasthenia Gravis
MG 992HunterSoleymaniMDClinical Eyelid Myotonia In Myasthenia Gravis
MG 10066Jonathan StroberMDSafety And Effectiveness Of Nipocalimab In Adolescent Participants In The Open Label Phase 2/3 Vibrance-Mg Clinical Study
MG 10116RyanVerityMDEfgartigimod Alfa-Fcab Use In A Pregnant Woman With Generalized Myasthenia Gravis: A Case Report 
MG 10243TuanVuMDEfficacy And Safety Of Nipocalimab In Patients With Generalized Myasthenia Gravis: Topline Results From The Double-Blind, Placebo-Controlled, Randomized Phase 3 Vivacity-Mg3 Study
MG 10353TuanVuMDRozanolixizumab In Patients Aged ≥65 Years With Generalized Myasthenia Gravis: A Post Hoc Analysis Of The Phase 3 Mycaring Study
MG 10479TuanVuMDNon-Steroidal Immunosuppressant Therapy Changes During Treatment With Zilucoplan In Patients With Generalized Myasthenia Gravis: 120-Week Follow-Up Of Raise-Xt
MG 10591TuanVuMDSafety And Efficacy Of Bcma-Directed Mrna Car T-Cell Therapy In Generalized Myasthenia Gravis
MG 10627HaiyanwangPh.D.Fast-Acting Treatment Of Myasthenic Crisis With Efgartigimod From The Perspective Of The Neonatal Intensive Care Unit
MG 10762Michael D.WeissMDConcomitant Intravenous Immunoglobulin Or Plasma Exchange Has No Effect On Complement Inhibition By Zilucoplan
MG 10842LaurenWilliamsB.S. BiologyClinical Experience With Rozanolixizumab For Treatment Of Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
MG 10938GeXiongMD, PhDA Retrospective Case Series Of Myasthenia Gravis Associated With Immune Checkpoint Inhibitors
MG 11050JingwenYanM.D.The Mitochondrial Quality Control Mechanism Of Statins Affecting Myasthenia Gravis Patients With Hyperlipidemia
MG 11130ShengGaoPhDPost-Hoc Analysis Of Clinically Relevant Anti-Vaccine Antibodies In Participants Treated With Nipocalimab
MG 112113LiZhangMDAcetylcholine Receptor Antibodies As A Biomarker Of Treatment Strategy With Rituximab In Myasthenia Gravis
MG 1136HuahuaZhongM.D.Plasma Biomarker-Based Endotyping Reveals Distinct Inflammatory Patterns In Myasthenia Gravis Subtypes
MG 11410MinZhuM.D., Ph.DLambert-Eaton Myasthetic Syndrome May Not Be Coincidental In Prostate Cancer